
Graham Collins/X
Dec 9, 2024, 20:06
Graham Collins: Real world 2nd line Lisocabtagene maraleucel
Graham Collins, Associate Professor, Haematology and lymphoma specialist at Oxford Cancer and Haematology centre, shared on X:
“Real world 2nd line Lisocabtagene maraleucel.
– 156 patients, med FU 6 months, many not transform-eligible.
– 70% CRR, 6mo PFS 61%.
– 6% G3/4 ICANS.
– Slight reduction in refractory vs early relapse and with age >70 years.
Largely reflects Transform data. Hoping it will come to UK soon.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 22, 2025, 16:16
Feb 22, 2025, 16:04
Feb 22, 2025, 16:00
Feb 22, 2025, 15:54
Feb 22, 2025, 15:48
Feb 22, 2025, 15:33
Feb 22, 2025, 15:14
Feb 22, 2025, 15:04
Feb 22, 2025, 14:43
Feb 22, 2025, 14:10
Feb 22, 2025, 13:28
Feb 22, 2025, 13:10